grace capital purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,000 shares of the company’s stock, valued at approximately $100,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Cubist Systematic Strategies LLC grew its holdings in shares of LivaNova by 22.2% during the second quarter. Cubist Systematic Strategies LLC now owns 2,404 shares of the company’s stock worth $240,000 after buying an additional 437 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in LivaNova by 6.8% in the second quarter. Crossmark Global Holdings Inc. now owns 7,410 shares of the company’s stock valued at $740,000 after purchasing an additional 470 shares during the period. Oregon Public Employees Retirement Fund grew its holdings in LivaNova by 3.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 17,026 shares of the company’s stock valued at $1,700,000 after purchasing an additional 490 shares during the period. Russell Investments Group Ltd. grew its holdings in LivaNova by 2.0% in the second quarter. Russell Investments Group Ltd. now owns 24,904 shares of the company’s stock valued at $2,487,000 after purchasing an additional 497 shares during the period. Finally, Cambiar Investors LLC grew its holdings in LivaNova by 9.9% in the second quarter. Cambiar Investors LLC now owns 6,036 shares of the company’s stock valued at $603,000 after purchasing an additional 545 shares during the period. Institutional investors and hedge funds own 86.92% of the company’s stock.

LivaNova stock opened at $124.79 on Friday. LivaNova PLC has a 1 year low of $67.95 and a 1 year high of $131.54. The company has a market capitalization of $6.36 billion, a P/E ratio of 37.96, a P/E/G ratio of 3.77 and a beta of 0.93. The company has a quick ratio of 1.08, a current ratio of 1.51 and a debt-to-equity ratio of 0.03.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, August 1st. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.04. LivaNova had a negative net margin of 4.93% and a positive return on equity of 9.24%. The firm had revenue of $287.50 million during the quarter, compared to the consensus estimate of $278.08 million. During the same period in the previous year, the firm earned $0.93 earnings per share. LivaNova’s revenue was up 12.4% compared to the same quarter last year. research analysts predict that LivaNova PLC will post 3.24 earnings per share for the current year.

In other LivaNova news, insider David S. Wise sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $102.04, for a total transaction of $153,060.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Douglas John Manko sold 2,058 shares of the business’s stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $121.61, for a total transaction of $250,273.38. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,558 shares of company stock valued at $627,103. 0.41% of the stock is owned by insiders.

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus restated a “buy” rating and issued a $135.00 target price on shares of LivaNova in a report on Thursday, August 2nd. BidaskClub upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, June 15th. Zacks Investment Research upgraded shares of LivaNova from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. Needham & Company LLC restated a “buy” rating and issued a $128.00 target price on shares of LivaNova in a report on Wednesday, July 18th. Finally, ValuEngine upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 27th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $102.67.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Read More: How to Invest in Growth Stocks

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.